Win-partners stock dividend – WIN-Partners Co Ltd Declares 36.0 Cash Dividend

March 18, 2023

Dividends Yield

On March 1, 2023, WIN-Partners Co Ltd declared a 36.0 cash dividend to shareholders. If you are looking for an investment with a steady dividend yield, WIN-PARTNERS ($TSE:3183) may be an attractive option. Their average dividend yield over the 2021-2023 period has been 3.62%. The annual dividend per share for the last three years have been 35.0, 35.0 and 34.0 JPY respectively.

This gives a corresponding dividend yield for 2021-2023 of 3.56%, 3.56% and 3.74% respectively. The ex-dividend date for this cash dividend declaration is on March 30, 2023. Therefore, those interested in benefiting from the dividend payout must ensure their shares are purchased before the ex-dividend date in order to be eligible for the cash dividend payout.

Price History

The company’s stock opened at JP¥1065.0 and closed at JP¥1060.0, from the last closing price of JP¥1064.0. This announcement has resulted in shareholders receiving a cash dividend of JP¥36.0 for each share held. By declaring this cash dividend, the company is aiming to reward its shareholders and increase investor confidence. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Win-partners. More…

    Total Revenues Net Income Net Margin
    68.89k 1.92k 2.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Win-partners. More…

    Operations Investing Financing
    2.85k -2.89k -1.28k
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Win-partners. More…

    Total Assets Total Liabilities Book Value Per Share
    41.9k 19.62k 755.28
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Win-partners are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    0.6% -8.1% 4.2%
    FCF Margin ROE ROA
    -0.6% 8.2% 4.3%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Win-partners Stock Fair Value Calculator

    At GoodWhale, we have conducted an analysis of WIN-PARTNERS‘s financials. Our proprietary Valuation Line has estimated the intrinsic value of WIN-PARTNERS shares to be around JP¥1055.7. Given that WIN-PARTNERS shares are currently being traded at JP¥1060.0, we believe this to be a fair price for the stock. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • Peers

    They have a wide range of products and services that are tailored to the needs of their clients, from medical equipment to solutions for healthcare facilities. They are well-known for their quality and customer service. Their competitors include Salus, Shenzhen Glory Medical Co Ltd, and PT Itama Ranoraya Tbk which are all well-established and respected providers in the medical and healthcare industries.

    – Salus ($LTS:0HMV)

    Salus is a medical device company that specializes in the development of innovative medical technology that improves patient health outcomes. As of 2023, the company has a market capitalization of 146.12 million dollars. Salus is known for its strong financial performance, as evidenced by its 13.73% return on equity. This ROE shows that the company is able to generate a high rate of return from each dollar invested in the company. As such, Salus is a great investment for many investors looking for a strong return on their money.

    – Shenzhen Glory Medical Co Ltd ($SZSE:002551)

    Shenzhen Glory Medical Co Ltd is a medical device and pharmaceutical company based in Shenzhen, China. The company specializes in producing medical equipment, drugs, and medical instruments. As of 2023, Shenzhen Glory Medical Co Ltd has a market cap of 3.94B and a Return on Equity of -1.55%. This market cap reflects the company’s current market value, and the ROE indicates that the company is not performing as well as expected. The negative return on equity might indicate that the company is not utilizing its resources effectively. Nonetheless, the company continues to be a leader in the medical device and pharmaceutical industry.

    – PT Itama Ranoraya Tbk ($IDX:IRRA)

    Itama Ranoraya Tbk is a Jakarta-based company that specializes in providing integrated solutions for industrial and infrastructure projects. The company has a market capitalization of 1.59 trillion as of 2023, which reflects its strong financial position. Its return on equity of 11.8% indicates that it is efficiently utilizing its resources to generate returns for its shareholders. Additionally, its diversified portfolio of businesses and its commitment to innovation are key factors driving the company’s success.


    Investing in WIN-PARTNERS can be a great way to diversify your portfolio and get consistent returns. With an average dividend yield of 3.62% over the 2021-2023 period, investors can expect to receive dividends of 35 JPY, 35 JPY, and 34 JPY per share, respectively. This translates to dividend yields of 3.56%, 3.56%, and 3.74%, respectively in the same period.

    Moreover, WIN-PARTNERS has a history of paying dividends consistently and has a high dividend yield relative to other stocks in the same industry. Investors should consider all of this information when deciding whether or not to invest in WIN-PARTNERS.

    Recent Posts

    Leave a Comment